Pharmacoeconomic Guidelines: Austria
Country/Region: Austria
Published PE Recommendations
Additional Information:
A working manual for the decision making process after an application to be listed on the positive list EKO
https://www.sozialversicherung.at/cdscontent/load?contentid=10008.555012
https://www.sozialversicherung.at/cdscontent/load?contentid=10008.555012
Information current as of Tuesday, January 21, 2020
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | Published PE Recommendations |
| Title and year of the document | Guidelines on Health Economic Evaluations (Concensus Paper 2006) |
| Affiliation of authors | Institute for Pharmaeconomic Research (IPF) in cooperation with an expert group |
| Purpose of the document | Providing recommendations for C/E studies and ensure a minimum standard of methodology and transparency |
| Standard reporting format included | No |
| Disclosure | Yes |
| Target audience of funding/ author's interests | Decision makers |
| Perspective | Apart from the societal perspective, other perspectives (e.g. health care system, social insurance,..) are possible |
| Indication | Yes |
| Target population | Be clearly specify |
| Subgroup analysis | Yes |
| Choice of comparator | Standard therapy, most frequent therapy or most effective therapy |
| Time horizon | Depends on research question |
| Assumptions required | Yes |
| Preferred analytical technique | CMA, CEA, CUA |
| Costs to be included | Costs relevant to the chosen perspective. Report indirect costs separately. |
| Source of costs | Latest unit prices, give references. |
| Modeling | Yes, requires details |
| Systematic review of evidences | Not stated |
| Preference for effectiveness over efficacy | Both acceptable |
| Preferred outcome measure | Depends on research question |
| Preferred method to derive utility | Should justify the selection |
| Equity issues stated | Yes |
| Discounting costs | 5%; SA:(3%-10%) |
| Discounting outcomes | 5%; SA:(3%-10%) |
| Sensitivity analysis-parameters and range | All key uncertain parameters, within a defined area, or probabilistic |
| Sensitivity analysis-methods | One-way, multi-way, may be probabilistic analysis |
| Presenting results | Must be reproduced transparently in disaggregated and aggregated form as for publication in peer reviewed journals |
| Incremental analysis | Yes |
| Total costs vs effectiveness (cost/effectiveness ratio) | Yes |
| Portability of results (Generalizability) | Yes; Studies must refer to the national context |
| Financial impact analysis | Possible |
| Mandatory or recommended or voluntary | Recommended |
Acknowledgement: